Drug Profile


Alternative Names: MPDL-3280A; RG-7446; RO 5541267; TECENTRIQ

Latest Information Update: 21 Apr 2017

Price : $50

At a glance

  • Originator Genentech; University Medical Center Groningen
  • Developer ARCAGY/GINECO Group; Astex Pharmaceuticals; Chugai Pharmaceutical; Clovis Oncology; Columbia University; Dana-Farber Cancer Institute; European Organisation for Research and Treatment of Cancer; Fondazione Michelangelo; Genentech; Immune Design; Incyte Corporation; M. D. Anderson Cancer Center; Roche; University Medical Center Groningen; University of California at San Francisco; University of California System; Yale University
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD274 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer; Urogenital cancer
  • Registered Bladder cancer
  • Phase III Breast cancer; Colorectal cancer; Fallopian tube cancer; Malignant melanoma; Ovarian cancer; Peritoneal cancer; Prostate cancer; Renal cell carcinoma; Small cell lung cancer
  • Phase II Chronic lymphocytic leukaemia; Soft tissue sarcoma; Solid tumours
  • Phase I/II Diffuse large B cell lymphoma; Follicular lymphoma
  • Phase I Acute myeloid leukaemia; Multiple myeloma; Myelodysplastic syndromes
  • No development reported Haematological malignancies

Most Recent Events

  • 21 Apr 2017 Roche plans a phase I trial for Ovarian cancer (Combination therapy, Second-line therapy or greater, Late-stage disease) in Australia and United Kingdom (NCT03101280)
  • 20 Apr 2017 Roche plans a phase III trial for Breast cancer (Combination therapy, First-line therapy, Inoperable/Unresectable, Late-stage disease) in Algeria, Argentina, Brazil, Canada, Croatia, Czech Republic, Egypt, Germany, Greece, India, Israel, Morocco, Saudi Arabia, Turkey, United Kingdom, Vietnam (NCT03125902)
  • 18 Apr 2017 Preregistration for Bladder cancer (Adjuvant therapy) in Canada (IV) before April 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top